Among 9 individuals with RP taking CGRP antagonists who exhibited microvascular complications, 4 (44%) had migraine with aura, which is nearly double the known prevalence of aura in patients with migraine (25%).18 Migraine with aura is an established risk factor for cerebrovascular and cardiovascular ischemia, particularly in women.19 Further studies are needed to evaluate the microvascular complication in individuals with migraine with aura who are taking CGRP antagonists. The gene discussed is CALCA; the disease is migraine disorder.